X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

VRNA

Closed

Verona Pharma Plc Adr

26.39
-0.64 (-2.37%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 27.03
Day's Range: 25.5 - 27.39
Send
When Written:
 
21.29
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company's lead product candidate, RPL554, is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4. RPL554 is currently in Phase 3 clinical trials for the treatment of COPD and Phase 2 trials for the treatment of cystic fibrosis. Verona Pharma is headquartered in London, UK and has a listing on the NASDAQ stock exchange under the ticker symbol VRNA.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:18.117.138.205
X